Thanks for your response, Kristyl. Can you explain the rationale for the MD/NP/RN to remain at the bedside? To my knowledge there is no monitoring required after administration. The MD/NP usually provides patient education, provides a copy of the patient agreement form, and answers any questions prior to administration. Looking forward to your response!
------------------------------
Quiere Robinson MSN, RN, AMB-BC
Ambulatory Nurse Clinician
VCU Health
Henrico VA
(804)773-9273
------------------------------
Original Message:
Sent: 10-28-2022 13:29
From: Kristyl McCray
Subject: CMA Scope of Practice in OBGYN
Hi Quiere
My organization is in California and the only POs not allowed to be administered by our MAs are anti-cancer drugs regardless of it's use. For this particular drug, I would have push back on giving in the clinic and request to be Rx for home use. if we decided to do this in our clinic, it would be required for the practitioner to remain at the bedside or an RN. I would be okay with an MA administering it with those steps in place.
------------------------------
Kristyl McCray MSN RN-BC
RN Clinical Director, Education & Prof. Practice
PIH Health Physicians
Whittier CA
(562)698-0811
Original Message:
Sent: 10-24-2022 14:54
From: Quiere Robinson
Subject: CMA Scope of Practice in OBGYN
Hi everyone
The CMA scope of practice is practically non-existent in Virginia and I am hoping for some guidance here. Does anyone's ambulatory OBGYN clinics allow medical assistants to administer PO mifepristone to patients in clinic? Why or why not? How did you determine this was acceptable or unacceptable? Looking forward to your responses, thank you!